Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.54 |
| ▸ | CTSB | P07858 | 2/20 | 0.54 |
| ▸ | CTSK | P43235 | 2/20 | 0.54 |
| ▸ | NAAA | Q02083 | 10/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27035108 | 0.78 | CTSL (0.58) | CTSLCTSBCTSKNAAAOPRM1 | |
| SCHEMBL25263042 | 0.75 | CTSL (0.44) | CTSLCTSBCTSKNAAAOPRM1 | |
| SCHEMBL21595610 | 0.75 | CTSL (0.44) | CTSLCTSBCTSKNAAAOPRM1 | |
| SCHEMBL14127576 | 0.74 | CTSL (0.43) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL19299990 | 0.72 | CTSS (0.51) | CTSLCTSBCTSKCARM1PRMT6 | |
| SCHEMBL425330 | 0.72 | CTSL (0.50) | CTSLCTSBCTSKNAAAOPRM1 | |
| SCHEMBL29132687 | 0.72 | CTSL (0.50) | CTSLCTSBCTSKNAAAOPRM1 | |
| SCHEMBL582674 | 0.72 | CTSL (0.50) | CTSLCTSBCTSKNAAAOPRM1 | |
| SCHEMBL22397634 | 0.71 | CTSL (0.58) | CTSLCTSBCTSKNAAAOPRM1 | |
| SCHEMBL6469380 | 0.70 | OPRM1 (0.59) | CTSLCTSBCTSKNAAAOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404275-B2 | Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2025-09-02 | — | — | US | disclosed |
| US-12129256-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2024-10-29 | — | — | US | disclosed |
| CN-113924301-B | Pyrazolopyrazine derivative compound, pharmaceutical composition and application thereof | 北京普祺医药科技股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| EP-3954689-B1 | PYRAZOLOPYRAZINE DERIVED COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE THEREOF | PRIMEGENE BEIJING CO LTD (CN) | 2024-04-24 | — | — | EP | disclosed |
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-11472809-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-11472809-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220204513-A1 | PYRAZOLOPYRAZINE DERIVED COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE THEREOF | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2022-06-30 | — | — | US | disclosed |
| US-20220204513-A1 | PYRAZOLOPYRAZINE DERIVED COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE THEREOF | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2022-06-30 | — | — | US | disclosed |
| US-9035074-B2 | Pyrrolo[2,3-D]pyrimidine derivatives | PFIZER INC. (US) | 2015-05-19 | — | — | US | disclosed |
| WO-2014128591-A1 | PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF JANUS- RELATED KINASES (JAK) | PFIZER INC. (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20140243312-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20130225556-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2013-08-29 | — | — | US | disclosed |
| US-8420629-B2 | Azetidine and cyclobutane derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2013-04-16 | — | — | US | disclosed |
| US-8158616-B2 | Azetidine and cyclobutane derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120077798-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2012-03-29 | — | — | US | disclosed |
| EP-2288610-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | Incyte Corporation (US) | 2011-03-02 | — | — | EP | disclosed |
| WO-2009114512-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | WO | disclosed |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129256-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | CBR3, CNR1, CBR1 | CTSL 2418/4885CTSB 3943/4885CTSK 3876/4885 |
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | CTSL 2468/4885CTSB 3891/4885CTSK 3957/4885 |
| US-20130225556-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | CTSL 3887/4885CTSB 1032/4885CTSK 2799/4885 |
| US-20220204513-A1 | PYRAZOLOPYRAZINE DERIVED COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE THEREOF | JAK2, TYK2, JAK1 | CTSL 4059/4885CTSB 4699/4885CTSK 1700/4885 |
| US-20090233903-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | CTSL 3887/4885CTSB 1032/4885CTSK 2799/4885 |
| US-12404275-B2 | Pyrazolopyrazine derived compounds, pharmaceutical composition and use thereof | JAK2, TYK2, JAK1 | CTSL 4059/4885CTSB 4699/4885CTSK 1700/4885 |
| US-20140243312-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES | JAK3, JAK1, JAK2 | CTSL 3215/4885CTSB 3778/4885CTSK 3004/4885 |
| US-20120077798-A1 | AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | CTSL 3887/4885CTSB 1032/4885CTSK 2799/4885 |
| US-11472809-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | SYMPK, IL15, STAT6 | CTSL 990/4885CTSB 3137/4885CTSK 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.